key: cord-0957404-ssnwcfvx
authors: Bakouny, Ziad; Hawley, Jessica E.; Choueiri, Toni K.; Peters, Solange; Rini, Brian I.; Warner, Jeremy L.; Painter, Corrie A.
title: COVID-19 and Cancer:Current Challenges and Perspectives
date: 2020-10-01
journal: Cancer Cell
DOI: 10.1016/j.ccell.2020.09.018
sha: 33ac0e616485e5cdca6fb8d9f355624d664f9c65
doc_id: 957404
cord_uid: ssnwcfvx

Patients with cancer have been disproportionally affected by the COVID-19 pandemic. This effect has included the adverse outcomes in patients with cancer who develop COVID-19, the impact of the COVID-19 pandemic on the delivery of cancer care, as well as the severe disruption to cancer research. However, patients with cancer are a heterogeneous patient population and recent studies have now documented factors that allow risk stratification of patients with cancer in order to optimize care. In this review, we highlight data at the intersection of COVID-19 and cancer, including the biological interplay between the two diseases and practical recommendations for the treatment of patients with cancer during the pandemic. We additionally discuss the potential long-lasting impact of the pandemic on cancer care, due to its deleterious effect on cancer research, as well as biological insights from the cancer research community that could help develop novel therapies for all patients with COVID-19.

Text Box 1 -Section 1:

• SARS-CoV-2 is internalized through binding to ACE2 and cleavage by TMPRSS2.

• ACE2 gene expression in the lungs correlates with smoking, which is frequent in patients with cancer.

• TMPRSS2 gene expression in the prostate is androgen receptor dependent but there is conflicting data on whether the androgen receptor regulates TMPRSS2 in lung tissue.

• Androgen targeted therapies, which are used in the treatment of prostate cancer, could limit SARS-CoV-2 infection by downregulating TMPRSS2 and/or stimulating an anti-SARS-CoV-2 immune response.

• Patients initiating some anti-cancer therapy for the first time may be considered for testing for SARS-CoV-2 using nucleic acid amplification for viral RNA (polymerase chain reaction, PCR).

• All patients undergoing cancer-directed therapy should be pre-screened using a standard questionnaire 48-72 hours prior to subsequent treatment cycles.

• If patients are positive on the "pre-screen" questionnaire they should be referred for PCR testing prior to treatment.

• If "pre-screen" is negative, they should be re-screened on day of treatment and if not symptomatic and without known exposure to COVID-19, they may be appropriate for treatment.

• Lung cancer and hematologic cancers and advanced or active cancers are associated with adverse outcomes upon SARS-CoV-2 infection.

The Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has resulted in an ongoing pandemic; at the time of writing (September 2020) over 30 million people have developed the resulting illness, COVID-19, causing more than 970,000 deaths worldwide (New York Times, 2020) . While the pandemic has, either directly or indirectly, impacted the entire world, certain subgroups of patients have been disproportionately affected. In particular, the Centers for Disease Control and Prevention (CDC) in the United States identify patients with certain medical conditions as being at particularly high risk of developing severe COVID-19 illness; among these are patients with cancer (CDC, 2020) .

Patients with cancer have been found to have particularly adverse outcomes with COVID-19 (Garassino et al., 2020; Giannakoulis et al., 2020; Kuderer et al., 2020; Pinato et al., 2020; Rivera et al., 2020; Saini et al., 2020; Westblade et al., 2020) .

Moreover, care delivery for chronic conditions, including cancer has been at least partially disrupted during the peaks of the pandemic due to prioritization and limitations in resources. Healthcare providers and patients have also had to continuously reassess the balance between the risks and benefits of cancer-directed interventions, within the context of the added risk of infection by SARS-CoV-2 (Schrag et al., 2020) . In addition to this disruption in cancer care delivery, cancer research has also been upended during the pandemic, including basic, translational, and clinical cancer research.

This review aims to comprehensively detail the relationship between COVID-19 and cancer, from biological interactions to specific clinical characteristics of patients with cancer who develop COVID-19, in the context of the reduced cancer care that the pandemic has brought on. The review will additionally highlight the potential lasting effect of COVID-19 on cancer care because of the significant interruption of cancer research.

J o u r n a l P r e -p r o o f

Multiple pieces of evidence have indicated an interplay between the biology of SARS-CoV-2 and cancer (Text Box 1). Evidence suggests that patients with cancer are more likely to be infected by SARS-CoV-2 Rogado et al., 2020) , more likely develop a severe COVID-19 infection (Garassino et al., 2020; Kuderer et al., 2020; Westblade et al., 2020) , and more likely to die as a result of COVID-19 (Garassino et al., 2020; Kuderer et al., 2020; Saini et al., 2020; Westblade et al., 2020; Williamson et al., 2020) . In contrast, certain anti-neoplastic hormonal treatments have been suggested to potentially play a protective role in patients with SARS-CoV-2 infections (Stopsack et al., 2020) . This clinical interaction between COVID-19 and cancer therefore warrants discussion of the potential underlying biological mechanisms. Envelope (E) protein and is coated by the Spike (S) protein (Andersen et al., 2020; Oberfeld et al., 2020) . SARS-CoV-2's spike protein plays a key role in viral binding to host cells and internalization: it has been shown to bind to the ACE2 surface receptor of epithelial cells in the respiratory tree and is subsequently cleaved by a host serine protease, TMPRSS2, to be internalized (Andersen et al., 2020; Hoffmann et al., 2020; Oberfeld et al., 2020) . Once the virus is within an endocytic vesicle, other proteases, such as the host cathepsin L (CTSL) protein, are thought to play a role in cleaving the S protein to release the single-stranded RNA into the host cell's cytoplasm Ou et al., 2020) . Given that multiple host proteins have J o u r n a l P r e -p r o o f been suggested to play a key role in SARS-CoV-2 infection, the evaluation of their expression patterns and of modulators of their expression have been recently studied ( Figure 1A ).

ii. Increased ACE2 expression and cancer ACE2, or Angiotensin-Converting Enzyme 2, is a membrane-bound enzyme that physiologically plays a role in maintaining blood pressure homeostasis by cleaving angiotensin II (Keidar et al., 2007) . ACE2 expression in lung tissue, where it is thought to play a key role in SARS-CoV-2 infection, has been suggested to increase with age Muus et al., 2020) . Since patients with cancer are, on average, older than the general population (Siegel et al., 2020) , this has been proposed to be one of the mechanisms mediating the particularly adverse clinical outcomes observed in older patients. However, the relationship between age and ACE2 expression in lung tissue is disputed by some other studies that have either found no relationship (J. C. or an inverse relationship (Booeshaghi and Pachter, 2020) between age and ACE2 expression in lung tissue.

In addition, multiple studies have recently found that ACE2 expression in lung tissue is increased in patients who smoke or who suffer from smoking-related lung diseases such as chronic obstructive pulmonary disease (COPD) (Baratchian et al., 2020; Pinto et al., 2020; . Moreover, there appears to be a dose-response relationship between number of pack-years of smoking and ACE2 expression (J. C. . Smokers are at increased risk of various cancers, and especially lung cancer (Siegel et al., 2020) , and both lung cancer (Garassino et al., 2020) and smoking (Kuderer et al., 2020) have been found to especially correlate with adverse outcomes in patients with COVID-19. It is therefore possible that these clinical findings are, in part, mediated by the increased expression of ACE2 in the lung tissue of smokers. The use of some antihypertensive therapies, such as angiotensin II receptor blockers or angiotensin converting enzyme inhibitors, has also been found to correlate with increased expression of ACE2 . However, no relationship between the use of these agents and the clinical outcomes of patients with COVID-19 has been found . J o u r n a l P r e -p r o o f iii. TMPRSS2 expression: insights from the field of prostate cancer research TMPRSS2, or Transmembrane Serine Protease 2, is a membrane-bound serine protease that has been studied in the context of prostate cancer, where it has been shown to be highly expressed and has been found to be implicated in gene fusions with members of the ETS family of transcription factors (particularly ERG) in up to 50% of primary prostate cancers (Stopsack et al., 2020) . TMPRSS2 expression is modulated by the androgen receptor (AR) in normal prostate tissue and prostate cancer (Lucas et al., 2014) . Beyond prostate tissue, it has been recently noted that TMPRSS2 is expressed in lung tissue at the mRNA and protein levels (Stopsack et al., 2020) .

However, it is still unclear whether the regulation of TMPRSS2 expression in normal human lung cells is androgen-dependent (as it has been shown to be in prostate tissue). TMPRSS2 gene expression has been found to be similar between males and females in normal lung tissue (Baratchian et al., 2020; Stopsack et al., 2020) , arguing against androgen-dependent regulation of TMPRSS2 in lung tissue.

Moreover, in mouse models, TMPRSS2 gene and protein expression in lung tissue did not decrease upon exposure to a potent AR antagonist, enzalutamide (Baratchian et al., 2020) . These findings contrasted with those of other studies that found TMPRSS2 to be upregulated by testosterone treatment in a lung adenocarcinoma cell line (A549) and that AR is a regulator of TMPRSS2 in these cell lines based on chromatin immunoprecipitation (ChIP) assays (Mikkonen et al., 2010) . In addition, TMPRSS2 expression in lung tissue has been found to correlate with the expression of androgen and estrogen-related pathways (X. , further suggesting that TMPRSS2 may be regulated by AR.

Clinically, a retrospective population-based study from the Veneto region in Italy reported that, although males generally had worse outcomes when they developed COVID-19, patients with prostate cancer who were treated by androgen deprivation therapy (ADT) were less likely to be infected by SARS-CoV-2, compared to patients with prostate cancer not on ADT and to patients with other tumor types (Montopoli et al., 2020) . In parallel, another retrospective study from a cancer center in the Northeastern United States found that patients with prostate cancer treated with ADT J o u r n a l P r e -p r o o f were less likely to develop adverse clinical outcomes (hospitalization and oxygen supplementation), compared to those not treated with ADT .

Randomized clinical trials that aim to evaluate the role of androgen-targeted therapies for the treatment of COVID-19 are currently ongoing. These clinical trials include those assessing agents that are currently part of the standard of care of management of prostate cancer, including AR antagonists such as bicalutamide (NCT04509999 & NCT04374279) and enzalutamide (NCT04475601) as well as gonadotropin-releasing hormone antagonists such as degarelix (NCT04397718).

b. Cancer, COVID-19, and the immune system There is evidence to suggest that the immune response to SARS-CoV-2 can play differing roles ( Figure 1B ). Patients who have certain forms of pre-existing primary or secondary immune suppression appear to be at increased risk of severe outcomes when they develop COVID-19 (Fung and Babik, 2020) , underscoring the importance of an intact immune system in limiting and responding to SARS-CoV-2 infection.

Conversely, the severe COVID-19 clinical syndrome, which develops in a subset of patients and is characterized by respiratory failure or death, has been attributed to a "cytokine storm" (Mangalmurti and Hunter, 2020) .

Although not yet strictly defined by clinical or laboratory criteria, this term has been used to refer to a hyperinflammatory state, biologically characterized by increased cytokine levels and clinically by an acute respiratory distress syndrome (ARDS)-like syndrome (Ackermann et al., 2020; Mangalmurti and Hunter, 2020) . Further evidence supporting the cytokine storm theory as a cause for adverse outcomes in patients with COVID-19 comes from the observation that patients with adverse outcomes with COVID-19 appear to have increased levels of pro-inflammatory cytokines, such as interleukin-6 (IL-6) (Cummings et al., 2020; Lucas et al., 2020; Mo et al., 2020; Qin et al., 2020; Robilotti et al., 2020; Wu et al., 2020) and the observation of a similar phenomenon with previous coronavirus epidemics, SARS (Huang et al., 2005) and MERS (Min et al., 2016) . Of note, an alternate hypothesis of the mechanism underlying the severe COVID-19 clinical syndrome has been termed "bradykinin storm". This hypothesis is mainly based on analysis of RNA-sequencing data from bronchoalveolar lavage samples showing that angiotensin converting enzyme (ACE) J o u r n a l P r e -p r o o f 13 is downregulated while ACE2 is upregulated in patients with COVID-19, compared to non-infected control patient samples. Since ACE physiologically reduces bradykinin and ACE2 increases bradykinin receptor-sensitizing peptides (angiotensin 1-9), these changes have been proposed to induce vasodilation, vascular hyperpermeability, hyaluronic acid accumulation, and consequently many of the clinical manifestations of severe COVID-19 (Garvin et al., 2020) . The "bradykinin storm" and "cytokine storm" hypotheses are also not entirely mutually exclusive since IL-2 has been found to be upregulated by bradykinin (Garvin et al., 2020) .

In patients with cancer, the immune system function can both be suppressed or hyper-activated, because of the disease itself or therapies used to treat it. Immune suppression is inherent to many cancer types and the development of cancer itself is thought to be, in part, due to a deficit in immune surveillance (Swann and Smyth, 2007) . Reversal of mechanisms of tumor immune evasion have led to effective anticancer therapies, namely immune checkpoint inhibitors (ICI) (Sharma and Allison, 2015) . Moreover, hematologic and solid tumors can increase the risk of various infections due to neutropenia, lymphopenia, disruption of anatomical surfaces (such as the nasal mucosa), splenic and humoral defects, and due to the administration of cytotoxic or other immune-suppressive therapies (Rolston, 2017; Safdar and Armstrong, 2011) . This immune suppression could be one of the factors implicated in the increased risk of infection by SARS-CoV-2 of patients with cancer Rogado et al., 2020) . Of particular interest to physicians is whether cytotoxic chemotherapy agents and targeted therapies could potentiate these SARS-CoV-2related risks and whether certain anti-cancer therapies need to be withheld. The biological interactions between the wide range of cancer-directed cytotoxic and targeted therapy agents and the immune system are very diverse. These effects include immune suppression and stimulation (such as through depletion of immune regulatory cells) and depend on the specific mechanism of action of each agent, as previously reviewed (Galluzzi et al., 2015) . Therefore, as discussed in detail from a clinical standpoint below, physician choices should be guided by the emerging evidence of safety of specific agents, patient-specific treatment goals, and contemporaneous assessment of the risk of SARS-CoV-2 infection (Schrag et al., 2020) .

However, cancer is also associated with a chronic pro-inflammatory state, with activation of the innate immune system (Coussens and Werb, 2002) , and anti-cancer immunotherapies have become part of the standard of care treatment of multiple cancer types. These therapies, including ICIs, bi-specific T-cell engagers (BiTEs), cytokines-bases therapies, tumor-infiltrating lymphocytes (TILS) or chimeric antigen receptor T (CAR-T) cell therapy, and allogeneic stem cell transplantation, lead to anti-cancer immune responses but also stimulate a general immune response that can affect normal healthy tissues, leading to immune-related adverse events (Postow et al., 2018; Waldman et al., 2020) . These immune-related adverse events can include pneumonitis, an often-severe inflammation of the lungs (Postow et al., 2018) . Beyond the decrease in respiratory reserve that pneumonitis entails, it is also the overlapping immune mechanisms of ICI-induced pneumonitis and COVID-19 pneumonia that could potentially increase the risk of immune-mediated lung damage in patients treated by ICI and who develop COVID-19 (Ackermann et al., 2020; Reuss et al., 2020) . In addition to the risk of lung-specific immune-related adverse events, immunotherapies pose the risk of systemic immune over-activation, which could hypothetically potentiate cytokine release, given that many of the same cytokines involved in ICI effectiveness also mediate the cytokine storm, such as interferon gamma (IFNγ), tumor necrosis factor alpha (TNFα), granulocyte macrophage colony-stimulating factor, and IL-2 (Berraondo et al., 2019; Chen and Mellman, 2013; Mangalmurti and Hunter, 2020) . This is especially true for CAR-T cell and BiTE therapy, a severe complication of which is cytokine release syndrome, a syndrome that shares many similarities with the cytokine storm associated with COVID-19 (Shimabukuro-Vornhagen et al., 2018) . The potential for interaction between immune therapies and SARS-CoV-2 infection has been further suggested by the recent finding that the expression of the receptor of this virus, ACE2, is upregulated by IFNγ, a downstream effector of immune therapies (Ziegler et al., 2020) . Clinically, receipt of ICI therapy for cancer has been associated with worse outcomes in patients with cancer who develop COVID-19 in one cohort (Robilotti et al., 2020) , although the same relationship was not found in another study (Jia Luo et al., 2020) .

The parallels between the mechanisms of immunotherapy-related toxicities and the COVID-19 cytokine storm has led investigators to evaluate cancer immunotherapy-J o u r n a l P r e -p r o o f inspired therapeutic agents. In particular, tocilizumab, an anti-IL-6 receptor antibody used in the treatment of BiTE-and CAR-T-induced cytokine release syndrome (Le et al., 2018; Teachey et al., 2013) , has been evaluated for the management of COVID-19 (Guaraldi et al., 2020; Ip, 2020; Jordan et al., 2020; Price et al., 2020; Somers et al., 2020) , including in patients with cancer (Rivera et al., 2020) . While some of these retrospective studies had suggested that a potential benefit was associated with tocilizumab in patients with COVID-19 (Guaraldi et al., 2020; Ip, 2020; Jordan et al., 2020) , a recent randomized placebo-controlled clinical trial evaluating tocilizumab, COVACTA (NCT04320615), did not meet its primary or secondary endpoints (based on a press release) (Genentech press release, 2020). Another anti-IL-6 receptor antibody, sarilumab, has also been evaluated in a randomized placebo-controlled clinical trial (NCT04315298), with a press release similarly reporting that it did not meet its primary or secondary endpoints and with the trial being discontinued in the United States (Regeneron press release, 2020). Despite these disappointing results, IL-6 inhibitors continue to be evaluated in clinical trials for the treatment of COVID-19 (NCT04412772; NCT04409262). Other therapies inspired from the care of patients with cancer have also been evaluated in patients with COVID-19. In a single arm, off-label, non-randomized prospective study, 19 patients with severe COVID-19 treated with acalabrutinib, a selective Bruton tyrosine kinase (BTK) that is used in the treatment of lymphoid malignancies, resulted in rapid improvement in oxygen requirements in most patients and precipitous reduction in inflammatory markers (including IL-6) (Roschewski et al., 2020) . Randomized clinical trials evaluating the treatment of patients with COVID-19 with BTK inhibitors are currently ongoing (NCT04439006, NCT04528667, NCT04346199). In a phase II randomized placebocontrolled clinical trial of 43 patients with severe COVID-19, treatment with ruxolitinib, a JAK1/2 inhibitor used in the treatment of myelofibrosis and polycythemia vera, tended to be associated with more rapid improvement of clinical, biologic (lymphopenia), and radiographic features of COVID-19 . The treatment of patients with COVID-19 with JAK inhibitors is currently being evaluated in multiple randomized clinical trials (NCT04477993, NCT04377620, NCT04390061, NCT04424056, NCT04366232). Corticosteroids have wide-ranging immunesuppressive functions that are believed to decrease the host immune-mediated lung damage following SARS-CoV-2 infection. These proposed benefits could be counterbalanced by the risk that this immune suppression may diminish anti-viral immune J o u r n a l P r e -p r o o f response, as has been previously suggested with MERS-CoV (Arabi et al., 2018) and SARS-CoV (Lee et al., 2004) , and more recently with SARS-CoV-2 (Westblade et al., 2020) . Clinically, Dexamethasone, a corticosteroid widely used in many medical applications including in the treatment of cancer, has recently been found to decrease the mortality of patients with COVID-19 who require respiratory support in a large randomized controlled trial (RECOVERY, 2020a), establishing its role in this setting. However, the question of whether this benefit applies to patients with cancer, a population of patients with specific immune features as outlined above, is not fully settled because the RECOVERY trial, that had established this benefit, did not specifically report on the outcomes of patients with cancer. Given the immune specificities of patients with cancer and their particularly high risk of developing adverse outcomes with COVID-19, future clinical trials should aim to specifically enroll and report on the outcomes of patients with cancer.

c. SARS-CoV-2 and Cancer: A perfect storm for thrombosis?

COVID-19 has been found to be associated with significant venous and thrombotic events ( Figure 1C ), with the relationship termed COVID-19 associated coagulopathy (Connors and Levy, 2020). Moreover, although the rate of symptomatic thrombotic events has been found to vary between 9% and 21% (Klok et al., 2020; Moll et al., 2020; Poissy et al., 2020) , one study that screened critically ill patients with COVID-19 using complete duplex ultrasound found that 100% of those on prophylactic anticoagulation had venous thromboembolic events compared to 56% of those on therapeutic anticoagulation (Llitjos et al., 2020) . This propensity to develop thrombotic events (including venous or, more rarely, arterial thromboses) appears to be, at least in part, related to inflammation and the activation of the innate immune Patients with cancer are particularly at risk of thrombotic complications since they have been found to have a 4 to 7-fold increased risk of having venous J o u r n a l P r e -p r o o f thromboembolic events compared to the general population (Lee, 2003) . This risk appears to vary by cancer type or stage, receipt of local or systemic therapy, and the presence of comorbidities (Falanga et al., 2013; Lee, 2003) . The inherent procoagulant state associated with cancer has been attributed to the expression by cancer cells of coagulation factors implicated in the extrinsic pathway of coagulation (such as tissue factor) and of pro-inflammatory factors (such as TNFα and IL-1β) (Falanga et al., 2013) . Clinically, a single center study evaluated venous thromboembolisms in patients with cancer who developed COVID-19. Patients who developed venous thromboembolic events had all been admitted to the intensive care unit (ICU), with a cumulative incidence of events of 9.3% of symptomatic VTE in ICU patients. Most patients with symptomatic VTE had developed these events early in their disease course, suggesting that the ICU stay was not a causative factor in these events but rather an indicator of severe COVID-19 disease (Moll et al., 2020) .

In another study comparing patients with active cancer to those without cancer who developed COVID-19, patients with active cancer did not have an increased risk of thrombotic events (arterial or venous) (Patell et al., 2020) . Despite the lack of clinical evidence thus far of increased thrombotic events in patients with cancer in small observational studies, the occurrence of occult thrombotic events cannot be discounted as being one of the potential factors in the increased rate of mortality due to COVID-19 in patients with cancer (Garassino et al., 2020; Giannakoulis et al., 2020; Kuderer et al., 2020; Williamson et al., 2020) , especially given the strong prior evidence of a pro-coagulable state in patients with cancer.

2. Defining and Identifying COVID-19 in patients with cancer a. Incidence and prevalence COVID-19 symptoms, 1-2% had concomitant cancer diagnoses. This was higher than the overall incidence of cancer in the general Chinese population (0.29%) . As the pandemic spread, data from Italy reported in April 2020 showed that, among patients with COVID-19 admitted to intensive care units, 81 of 1591 (8%) patients had active or prior malignancy (Grasselli et al., 2020) . Similarly, reports of patients with COVID-19 at two large academic healthcare systems in New York showed that 6-7% of patients hospitalized with COVID-19 had active cancer (Argenzian et al., 2020; Richardson et al., 2020) .

Reasons for the documented elevated prevalence of COVID-19 among patients with cancer may be due to biologic and immunologic factors, discussed above, that predispose patients to COVID-19. However, it is also possible that non-biologic factors may contribute to the relative increase in prevalence: for example, the increased frequency of interfacing with the healthcare system due to cancer treatment and surveillance as well as the close relationships that cancer patients have with healthcare staff perhaps leading to expedited testing in cancer patients with any symptoms.

Based on symptomatology alone, the clinical presentation of COVID-19 in patients with cancer does not differ compared to patients without cancer. Patients generally experience fever, chills, myalgias, respiratory symptoms, sore throat, and/or loss of taste or smell (Kuderer et al., 2020; . Although the clinical spectrum of COVID-19 is heterogeneous, patients with active malignancy experience more severe disease and higher observed death rates from COVID-19, which have ranged between 5% and 61%, with a recent meta-analysis based estimate of 25.6% (Dai et al., 2020; Giannakoulis et al., 2020; Kuderer et al., 2020; Mehta et al., 2020; Saini et al., 2020) .. The two most widely used laboratory tests for SARS-CoV-2 include nucleic acid amplification tests (RT-PCR) and antibody (serology) tests. The preferred testing method for screening and diagnosis is the reverse transcription-polymerase chain reaction (RT-PCR) test, while the antibody-based tests serve as supplemental tools for tracking immune response (Tang et al., 2020) . During the early days of the outbreak in China, both oropharyngeal (OP) and nasopharyngeal (NP) swabs were used for testing and diagnosis. However, the NP swab became preferred after data showed that SARS-CoV-2 RNA detection was 32% in OP swabs compared to 63% in NP swabs (W. . The NP swab is the primary test currently used in screening algorithms for patients and healthcare employees. While the NP RT-PCR test is sensitive, specific and able to be processed in large batches of samples, the turnaround time can be on the order of weeks. A point-of care test, with results available in minutes, could change the nature of the pandemic with respect to clinical care and political mandates (Wolters et al., 2020) .

The ASCO guidance on "Cancer care delivery during the COVID-19 pandemic" discussed below is based on recommendations from the Infectious Disease Society of America, and is particularly helpful regarding the procedure for implementing a pre-screening and screening program in the ambulatory setting (ASCO, 2020b). In all cases of symptomatic patients, whether in hospital or ambulatory setting, the recommendation is to test (Text Box 2). Similarly, all patients who are initiating treatment with cytotoxic chemotherapy, stem cell transplantation, long acting biologic therapy, cellular immunotherapy, or high-dose corticosteroids for the first time should be considered for testing 48-72 hours before initiation of therapy, although this is not J o u r n a l P r e -p r o o f an international recommendation. Prior to subsequent cycles, patients should be prescreened 48-72 hours using a standardized questionnaire addressing symptoms and potential exposure. If patients have history of COVID-19 exposure, respiratory symptoms, or two other symptoms (cough, shortness of breath, fever, chills, myalgias, sore throat, new loss of taste or smell, or other flu-like symptoms) they should be triaged to testing. It is recommended to have testing performed at a site other than the cancer care facility if able to avoid bringing positive cases into cancer treatment facilities. If patients have a negative pre-screen, defined by lack of symptoms and no close or proximate contact with anyone who tests positive for COVID-19, they should present to care on the planned treatment day. Upon arrival to the healthcare facility, patients should again be screened to determine if there has been a change in status and/or need for testing or retesting.

In few cases, asymptomatic chronic carriers have been identified. In this situation, data suggest that it is best to observe for a period of time and monitor for COVID-19 symptomatology prior to administering treatment. Recent analysis of test results from asymptomatic patients (1988 tests from 1226 patients) undergoing chemotherapy from the UK Birmingham Chemotherapy Cancer COVID-19 cohort revealed that the asymptomatic prevalence is 0.6% (Lennard Y.W. Lee et al., 2020b) . Follow-up data on rates of symptomatic disease is not currently available. Although a smaller analysis, data from a universal pre-chemotherapy testing program at a hospital in Dubai, United Arab Emirates (UAE) revealed that seven of 85 asymptomatic patients with cancer were positive by PCR screening (8.2%; 95% CI, 2.4-14.1%), all of whom subsequently developed symptomatic disease (Al-Shamsi et al., 2020) . It should also be noted that the rates of asymptomatic carriage are directly linked to the rate of infection where studies are performed. These data underscore the principle of early detection of pre-symptomatic patients and risk mitigation with COVID-19 in the context of cytotoxic and myelosuppressive or immunomodulatory treatments.

If a patient has a positive test result, an immediate treatment break or delay is warranted. However, some patients may still be able to receive treatment if they are on low-risk regimens, if disease burden mandates to undertake such a risk and provided there is a designated COVID-19 treatment area or linear accelerator (LINAC) with dedicated staff are in place. When or if to restart treatment after a positive test result is not clearly defined by published guidelines. However, expert J o u r n a l P r e -p r o o f consensus in line with ASCO guidelines is anchored on consideration of the context of medical necessity. Some providers may retest to ensure two successive negative PCR tests a minimum of 24 hours apart, unless testing is unavailable, or not required by local guidelines, however long-term shedding does occur and underscores the necessity of using clinical context and judgement. Indeed, additionally and often exclusively, only both criteria of a complete clinical recovery at least 10-14 days since symptom onset, without fever or significant symptoms for at least 48-72 hours are mandated. Available data suggest that, once symptoms have resolved, persistent viral shedding can be observed for up to 66 days leading to positive PCR tests after recovery may not represent infectiousness, but this is an area of ongoing investigation (Agarwal et al., 2020; Bullard et al., 2020) . Planning for and ensuring a robust supply chain and inventory of PPE are essential to all healthcare centers as the pandemic continues. Data from a survey of 343 oncologists from 28 countries with a self-reported COVID-19 outbreak (99.7%) reported that PPE was available to all participants (Ürün et al., 2020) . It should be noted that the type of PPE used by the participating oncologists varied and while J o u r n a l P r e -p r o o f eye goggles/glasses and N95 masks, respectively. Moreover, the responses to the survey were recorded between April 1 st and 29 th , 2020, during which time the incidence of COVID-19 infection varied widely across the geographically diverse respondents to the survey. Therefore, while this survey is somewhat reassuring in that it shows that oncologists had some degree of PPE available during the pandemic, its results should be noted with caution given the diversity in the type of PPE that was used by the responding oncologists and the fact that the survey responses may have not been recorded during the peaks of the pandemic in the respective geographic regions, when PPE would be most at risk of being scarcely available.

Optimization of reuse and of filtering facepiece respirators, return to work policies for infected healthcare professionals, work-from-home policies, attention to stress management, and providing mental health resources are all additional components of an effective cancer care delivery model during the COVID-19 pandemic.

In addition to the drastic changes to everyday life, the COVID-19 pandemic poses unique challenges to the delivery of oncologic care and is forcing us to redefine cancer care delivery models. Key to clinical practice changes is adapting to the specific scenario in which each community exists over time (Harky et al., 2020) .

Practice patterns will continue to evolve as the locoregional case volume and phases of reopening ebb and flow.

Telehealth has come to the forefront of clinical care during the COVID-19 pandemic.

Although it may not be right for every patient and every situation such as goals of care discussions, it provides a safe and easy way for patients to access their doctors at a time when human contact and mobility present substantial health risks due to the high transmissibility of the SARS-CoV-2 virus.

On March 30, 2020 the US Center for Medicare & Medicaid Services' (CMS) issued the 1135 Waiver, loosening regulations and allowing for expansion of coverage for J o u r n a l P r e -p r o o f telehealth services to Medicare beneficiaries. Although some centers had been early adopters of telehealth in the pre-COVID era to fill gaps in care that resulted from provider shortages, after the 1135 Waiver was issued, nearly all centers reconfigured care delivery models focusing on the expansion of telehealth capabilities (Royce et al., 2020) . CMS issued further clarification detailing regulatory changes, including lifting of telehealth restrictions on urban areas, new patient visits, HIPAA regulations, remote supervision of services rendered, and supervision of resident physicians (Royce et al., 2020) . Perhaps most importantly, CMS clarified that telehealth services paid under the Physician Fee Schedule is the same as in-person services (CMS, 2020) .Although these regulations apply to Medicare beneficiaries, many private payers and state Medicaid programs have announced expanded coverage as well. Despite these relaxed policies, challenges remain. For example, a telehealth appointment where the patient is physically in another state from the clinician is considered to cross state lines, and the clinician must have an active license in the state where the patient resides. Emergency licenses have been granted but whether these programs will continue is unclear (Hollander and Carr, 2020) . At a global level, telehealth may impose billing and reimbursement barriers, additionally to a significantly different organization of work, as well legal context.

The degree to which telehealth may impact quality and outcomes in cancer care is still being defined. One can look back to data from the pre-COVID era, which in a brief prepared for the Agency for Healthcare Research and Quality (AHRQ) showed evidence of effectiveness for remote monitoring of patients, communication and counselling for patients with chronic conditions, and providing behavioral support and psychotherapy (Tuckson et al., 2017) . Furthermore, a Cochrane systemic review of 93 trials (N = 22,047 participants) evaluated the effectiveness of telehealth as an additive, alternative, or comparison to usual care across several clinical conditions. This review found no difference in all-cause mortality (Flodgren et al., 2015) . In fact, the study found an increase in quality of life for those allocated to telehealth as compared to usual care, and improved disease control in diabetes, hypercholesterolemia, and hypertension. From the oncologic side, results from a meta-analysis of 20 randomized-controlled trials which assessed the effect of telehealth intervention versus usual care in patients with breast cancer showed that telehealth was associated with a higher quality of life and self-efficacy, and less J o u r n a l P r e -p r o o f depression and distress compared to usual care (Chen et al., 2018) . Specific to the COVID-19 pandemic, additional advantages of telehealth include reducing PPE demands, limiting exposure, and reducing travel and wait times for patients.

However, appropriate patient selection for telehealth oncologic care is key. Both ESMO (ESMO, 2020)and ASCO (ASCO, 2020a)suggest that patients not requiring in-person exam, treatment, or diagnostics should have telehealth visits during the COVID-19 pandemic. Specifically, telehealth visits are appropriate if the primary reason for the clinic encounter is to follow-up on treatment adherence for oral agents, survivorship, genetic counselling, supportive services, or education. Implementation guides and toolkits are published to assist with the rapid integration of outpatient telehealth programs (W. R. .

It is also important to consider the unintended consequences of widespread adoption of technology. There is a serious potential risk of compounding health disparities between patients of different socioeconomic status, if telehealth services are mandated. This has been recently highlighted by a multi-center prospective cohort study showing that, among patients with cancer in the Northeastern United States, Black and Hispanic patients were less likely to benefit from telehealth visits, compared to White patients . Care should therefore be taken to assess tech-literacy and digital services before scheduling services (Elkaddoum et al., 2020), and healthcare professionals should attempt to minimize disparities in the use of telehealth by evaluating the barriers to adoption.

Global interruptions to cancer screening began with national and state lockdowns.

Many patients, providers, and healthcare institutions temporally suspended routine cancer screening and diagnostic procedures until the appropriate provisions and safety measures (institutional protocols, testing capabilities, and PPE inventory) were in place. As a result, routine screening dropped by as much as 85-90% (London et al., 2020) . Now as some healthcare centers inch towards a new normal, many are struggling with management of the backlog of cases. In the UK, for example, it is estimated that 1 million people have not been invited to colorectal cancer screening and approximately 8500 people who received a positive fecal J o u r n a l P r e -p r o o f immunochemical test (FIT) by mail before the national lockdown are currently awaiting an appointment for a follow-up colonoscopy (The Lancet Gastroenterology & Hepatology, 2020) . Based on the importance of early screening and detection, combined with effects of treatment delays, it is perceived, but not characterized, that delays in diagnosis during the pandemic may negatively impact cancer outcomes.

In a population-based modelling study from the UK assessing the impact of diagnostic delays on survival in breast, colorectal, esophageal, and lung cancer, substantial increases in the number of avoidable cancer deaths are expected to result. In this model, the increase in deaths 5 years after initial diagnosis may be 4-17% higher, depending on tumor type, due to diagnostic delays during the COVID-19 pandemic compared to pre-pandemic figures (Maringe et al., 2020) . Similarly, in another observational modelling study from the UK, delays of 3-6 months in surgery for incident cancers would decrease life-years gained by said surgery 19%/43%, respectively, and 26/59% when considering resource-adjusted life-years gained (Sud et al., 2020) .

ASCO (ASCO, 2020a) and ESMO (ESMO, 2020) guidelines recommend that cancer care screening services, including colonoscopies, pap smears, and mammograms, resume in accordance with state and local health authorities. Expanding existing capacity as rapidly as possible should be at the forefront of cancer care delivery systems' efforts.

c. Cancer-Directed Therapy during the COVID-19 Pandemic i. Surgical Oncology During peak numbers of COVID-19 cases in a community, nearly all nonurgent or "elective" surgeries have been delayed, as reported in studies from MD Anderson Cancer center (Chang and Liu, 2020) and the University of Alabama-Birmingham . The impact on future cancer progression and death as a result of current delays in "elective" cancer surgeries are not yet known. However, investigators from England used hazard ratios from observational studies from 2013-2017 to model cancer progression and loss of life-years due to surgical delays. They estimated that a 3-and 6-month delay to surgery across all stage 1-3 cancers would cause 4,755 and 10,760 deaths among the 94,912 patients undergoing resections for major cancers per year (Sud et al., 2020) . For now, many surgical oncologists and multi-disciplinary treatment teams are focused on prioritizing surgeries based on clinical rationale, and potential alternative non-surgical management strategies, with decisions being based on locally available resources in line with the American iii. Radiation Therapy Radiation therapy, a prominent pillar in cancer care given its often curative and palliative role, has similarly been affected by the COVID-19 pandemic. The American J o u r n a l P r e -p r o o f Society of Radiation Oncology (ASTRO) surveyed a wide variety of US radiation oncology community and academic practices to assess the initial impact and operational responses to the COVID-19 pandemic. All practices reported uninterrupted operation, however on average the typical volume had decreased to 68% (range, 10-95%). Treatment delays were reported by 92% of practices, with the most delays of treatment for low-risk prostate (88%) and early stage breast cancer (73%). However, the treatment of more aggressive tumor types (such as gastrointestinal, central nervous system, and small cell lung cancers) was delayed by less that 15% of practices, suggesting the safety and importance of providing this essential and non-elective treatment for many cancer types. Adding to this, reports from China and Italy showed that very few patients required treatment interruptions in radiotherapy services, and few patients undergoing radiotherapy were diagnosed with COVID-19 during their treatment course (0.48%, 1 of 209 patients) (Krengli et al., 2020; Xie et al., 2020) . As per ASTRO's "COVID-19 Clinical Guidance

Resources" it is imperative that services are provided with robust prevention and that infection control measures be put in place (ASTRO, 2020).

Cancer clinical trials have also been critically impacted by the pandemic, with outright halting of all enrollment at some centers during the peak case volume. A cohort study assessing the effects of the pandemic on national enrollment in cancer clinical trials conducted by the SWOG Cancer Research Network showed a decrease in enrollment from 125 to 150 patient enrollments per week in early January (week 1) to 74 enrollments per week near the end of the study period (week 17) (Unger et al., 2020) . In March 2020, ASCO surveyed 64 investigators at academic and community practices on the conduct of clinical trials during the COVID-19 pandemic. Nearly 60% of respondents' programs reported halting screening and/or enrollment for certain trials, 50% of respondents' programs ceased research-only blood and/or tissue collections, and 65.6% of site initiation visits were conducted remotely (Waterhouse et al., 2020) . Additionally, tier-based approaches to prioritizing trials were utilized at 53.1% of respondents' programs. Challenges noted to continuing clinical trial investigations during the pandemic include patients' inability J o u r n a l P r e -p r o o f to return to healthcare centers for study visits especially if they are traveling from outside the state and have quarantine measures to abide, the limited availability of ancillary services, and the challenge of holding timely discussions with sponsors and contract research organizations (CROs). However, as noted by Waterhouse et al., some positive clinical trial-related lessons are worth perpetuating forward to the post-COVID era. Trialists should continue to streamline visits and create more flexible study timelines, leverage telehealth to limit in-person visits, and use of e-signatures for trial documentation (Waterhouse et al., 2020) , while trial sponsors should continue to demonstrate increased flexibility with regards to trial protocols. This opportunity to reform how we conduct clinical trials moving forward represent potential areas of improvement for the future . For instance, incorporating telehealth visits and remote consent routinely into clinical trials, as has been done during the pandemic for some clinical trials , could help render trials more accessible and consequently trial patient populations more representative of real-world patient populations. Crucially, a recently reported experience from Dana-Farber Cancer Institute demonstrates that the incorporation of telemedicine and mailing of oral investigational agents during the pandemic was not associated with increases in serious adverse events or major violations related to drug dosing (Tolaney et al., 2020) .

The RECOVERY trial, while evaluating COVID-19 directed therapies and not cancerdirected treatments, is a striking example of how randomized controlled trials can be conducted efficiently, cheaply, and collaboratively when regulatory requirements are relaxed and clinical trial protocols are simplified (Emanuel et al., 2020) .This trial has thus far shown that dexamethasone is effective in the treatment of patients with COVID-19 who require respiratory support (RECOVERY, 2020a) , and that the lopinavir-ritonavir combination (RECOVERY, 2020b) and hydroxychloroquine (Horby et al., 2020) are not effective in the treatment of COVID-19.

There are ongoing large national and international efforts to characterize and understand the impact of the COVID-19 pandemic within the oncologic community. Although patients with cancer are now recognized to be at increased risk of adverse outcomes with COVID-19 (Garassino et al., 2020; Giannakoulis et al., 2020; Kuderer et al., 2020; Williamson et al., 2020) , this patient population is large and relatively heterogeneous. Identifying patients that are at particularly increased risk is essential for risk stratification, tailoring prevention measures, and cancer and COVID-19 treatment. As such, multiple studies have attempted to determine prognostic factors in patients with COVID-19 in general, or specifically within the subgroup of patients with pre-existing diagnoses of cancer ( Tumor-related factors appear to be a significant prognostic factor in patients with cancer. In particular, certain tumor types have been found to be associated with particularly poor outcomes with COVID-19. These include lung cancer (Dai et al., 2020; Garassino et al., 2020) , potentially due to reduced respiratory reserve, and hematological cancers (Dai et al., 2020; He et al., 2020; Kuderer et al., 2020; Lennard Y W Lee et al., 2020; Passamonti et al., 2020; Williamson et al., 2020) , perhaps due to the inherent immune suppression that is associated with the cancer itself and the more immune-suppressive therapeutic regimens that are often used to treat these cancers .

Beyond the type of cancer, it is also the status of the tumor (active -stable or progressing, or in remission) that seem to impact the prognosis of patients with cancer who develop COVID-19. Patients with advanced cancer as well as progressing diseases have been consistently found to have worse outcomes (compared to those with localized disease or who are in remission) (Albiges et al., 2020; Dai et al., 2020; Kuderer et al., 2020; Passamonti et al., 2020; Pinato et al., J o u r n a l P r e -p r o o f general poorer health status of patients with more advanced cancer disease, impacting treatment strategies adopted while driven by the cancer prognosis (e.g., earlier referral to comfort-based care), or whether advanced or progressing cancers affect the COVID-19 disease course due to intersecting biological mechanisms with SARS-CoV-2, as discussed above.

ii. Receipt of systemic cancer-targeted therapy As discussed above, some general guiding principles have emerged with regards to systemic cancer-targeted therapies (Schrag et al., 2020) There are currently conflicting data on the association between receipt of systemic therapy and prognosis. In particular, receipt of ICIs (Robilotti et al., 2020; Tian et al., 2020) and chemotherapy (Albiges et al., 2020; Lennard Y W Lee et al., 2020) was associated with poor outcomes in patients with cancer and COVID-19 in some studies, but other studies had reported no association (Kuderer et al., 2020; Lennard Y.W. Lee et al., 2020a; Passamonti et al., 2020) . However, it should be noted that the absence of conclusive evidence to the association between receipt of systemic therapy and adverse COVID-19 outcomes should not be taken for evidence of absence of an effect. In particular, each of these studies is likely only powered to detect relatively large effects and group systemic therapies into groups of therapies with related mechanisms of action. The effects of less frequently used systemic therapies (such as experimental therapies and specific combination regimens) are thus far largely unexplored. Moreover, the potential for interaction between systemic therapy regimens and cancers that predispose to worse COVID-J o u r n a l P r e -p r o o f Therefore, caution should prevail when treating patients with cancer during periods of COVID-19 resurgence and the benefits and risks of each therapy should be weighted during consultations with patients (Schrag et al., 2020) .

iii. Social determinants of health While the pandemic has, at the time of this writing, hit most countries in the world, patient populations have been unevenly affected, even within the same countries or geographic regions. In particular, in the United States and in the United Kingdom, race and ethnicity have appeared to be important correlates of rates of infection and of adverse outcomes in patients with COVID-19 in general (Chowkwanyun and Reed, 2020; Williamson et al., 2020; Yancy, 2020) . This result mirrors the relationship previously observed between adverse outcomes in other diseases, including cancer, and race and ethnicity (Badal et al., 2020; Marinac et al., 2020; Marinaro et al., 2020; Yedjou et al., 2019) . These health disparities are thought to be largely driven by socio-economic status, lack of sufficient access to care, and area of residence, but biological factors have been implicated in certain instances (although not with COVID-19).

Whether health disparities are also pronounced in patients with cancer who develop COVID-19 has not been fully established. However, it seems plausible that this relationship, between being part of racial or ethnic minorities and adverse COVID-19 outcomes, would hold or even be more pronounced in patients with cancer. In fact, there are early signals to this effect from certain studies of patients with cancer and COVID-19, with one study suggesting that Black patients with cancer are half as likely to receive remdesivir for COVID-19 compared to white patients (Rivera et al., 2020) . Furthermore, others suggest that health disparities with regards to cancer care are more likely to become accentuated during the COVID-19 crisis due to socioeconomic factors and decreased access to telehealth services (Balogun et al., 2020) . Lee et al., 2020a; Pinato et al., 2020) , older age (Albiges et al., 2020; Garassino et al., 2020; Kuderer et al., 2020;  Lennard Y.W. Lee et al., 2020a; Passamonti et al., 2020; Pinato et al., 2020; Robilotti et al., 2020; Tian et al., 2020; Westblade et al., 2020) , comorbidities (including cardiovascular and respiratory) (Garassino et al., 2020; Kuderer et al., 2020; Lennard Y.W. Lee et al., 2020a; Pinato et al., 2020) , smoking (Albiges et al., 2020; Garassino et al., 2020; Kuderer et al., 2020; , and poor general performance status (Albiges et al., 2020; Kuderer et al., 2020; Tian et al., 2020) . Many of these factors are associated with cancer itself and this may account for the general poorer prognosis of patients with cancer who develop COVID-19.

In addition to clinical factors, prediction of outcomes of patients who develop COVID-19 could be refined by including biomarkers or laboratory results. For instance, a recent study has found that increased IL-6 and TNFα, which are both thought to be involved in the COVID-19 cytokine storm, can predict adverse outcomes in patients with COVID-19, independently of other clinical factors (Del Valle et al., 2020) . Other potential biomarkers have included neutrophil count, lymphocyte count, C reactive protein level, platelet count, and creatinine, among others (Wynants et al., 2020) .

These findings have been corroborated in patients with cancer, whereby inflammation markers (increased in IL-6, TNFα, CRP, procalcitonin, ferritin, and Ddimer) (Albiges et al., 2020; Tian et al., 2020) , markers of organ damage (decreased albumin, increased cardiac enzymes and LDH) (Albiges et al., 2020; Tian et al., 2020) , and markers of immune dysfunction (decreased lymphocytes, monocytes, and CD4 + T cells) (Albiges et al., 2020; Tian et al., 2020) have all been associated with adverse prognosis. In addition to patient-specific biomarkers, increased SARS-CoV-2 viral load has been recently found to be a predictor of adverse prognosis in patients with or without cancer (Westblade et al., 2020) .

J o u r n a l P r e -p r o o f c. Prognostic models and collaboration While these correlates of prognosis are important to inform clinical practice, developing prediction models that accurately predict patient outcomes and that are usable in clinical practice could help triage patients, focus resource utilization, and serve as stratification factors in clinical trials. Unfortunately, a recent review of predictive models for patients with COVID-19 in general concluded that despite the fact that a multitude of models have so far been published, none are currently usable in clinical practice (Wynants et al., 2020) , largely due to insufficient reporting and high risk of bias.

In particular, patients with cancer form a relatively small proportion of the overall number of patients infected with COVID-19 and multiple studies have not specifically reported on whether the patients included had a cancer diagnosis. This raises concerns with regards to the generalizability of existing models to patients with cancer. Developing predictive models that are specific to patients with cancer or validating existing models in patients with cancer will require multi-institutional collaborations to assure adequate statistical power and generalizability. Fortunately, multiple multi-institutional initiatives are currently working on aggregating data on patients with cancer including the COVID-19 and Cancer Consortium (CCC19) , ESMO CoCARE, Thoracic cancERs international coVid 19 cOLlaboraTion (TERAVOLT) (Whisenant et al., 2020) , the UK Coronavirus cancermonitoring project (Anil et al., 2020) , and others, as previously described Palmieri et al., 2020) .

The effects of the COVID-19 pandemic are wide ranging. In addition to impacting patients and providers, cancer researchers have also had their routine research lives upended. As noted in a letter from the AACR directors to the U.S. Congress (AACR, J o u r n a l P r e -p r o o f 2020), many researchers admirably contributed to the global and national interest by repurposing their cancer research labs to help address the needs of combating the pandemic (Figure 2 ). Their labs and facilities helped develop novel tests, aided in drug screens, conducted vaccine research, and analyzed population cohort data.

This shift in research focus has been made possible by increased flexibility in federal grant mechanisms. Specifically, the National Institutes of Health offered Urgent and Emergency competing revisions and administrative supplements to existing grant awards on a rolling basis. When COVID-19 research is proposed, it is considered as "in (or out) of the scope" of the parent grant, with a broad interpretation of "in the scope," because virtually no NCI grantees have COVID-19 grants (Singer, 2020 (Webster, 2020) . The impact on cancer research funding is therefore likely to be felt globally, with governments and philanthropic organizations around the world having to take similar measures due to the unforeseen challenges posed by the pandemic.

In addition to shifting the focus of laboratory-based research and the effects on funding, cancer researchers have had their scientific investigation, home life, and professional interactions uprooted. In many cases, the ability to perform experiments was altogether halted as institutions and labs were shut down entirely (Colbert et al., 2020) . Reopening is largely dependent on local benchmarks and institutional preparedness. After state and local mandates to shelter in place were invoked, many researchers have been additionally faced with duties including caring for family members and home-schooling children. Although this change in work-from-home conditions was universal, using academic metrics to determine whether certain populations have been disproportionately affected (i.e. parents of school-aged children, women, members of underrepresented minority groups, urban vs. rural colleagues, early career vs. mid-career vs. established investigators), will be informative. Levine and Rathmell write in a call-to-action editorial (to support early career investigators), that "reduced productivity during this time (pandemic closures) can produce an undesirable 'flattening of the curve' that is potentially unrecoverable (Levine and Rathmell, 2020) . The in-person connections and networking opportunities that so often define academic conferences have gone by the wayside, with virtual events taking their place in the COVID-era. Whether or not people prefer to consume data and science from their living room or backyard is not as crucial a question as what the long-term losses to the scientific community might be from not interacting, congregating around posters, riffing on pathways, and forging new collaborations. While many of the virtual events have been highly effective and seamless in delivering material, whether or not the same enthusiasm and facilitation of future collaborations are born from virtual events is not immediately clear. We must be intentional about creating opportunities to interact spontaneously with each other, especially meeting new people. A useful exercise might be to compare the number of multi-institutional grant applications and publications over the next 1 to 2 years to years past, and to delineate how many of them are new collaborations or include and feature an early career investigator. Within CCC19, we are intentional about putting early career investigators and members from underrepresented minority groups out front and featured on prominent publications. It is critical that everyone in the scientific research community recognize that while the COVID era is J o u r n a l P r e -p r o o f difficult for us all, the effects are not shared equally. Now is the time to lift each other up.

And finally, it is worth highlighting that efforts to prevent and treat other noncommunicable diseases (NCD), including cancer, have been upended by the COVID-19 pandemic. Pre-COVID, the World Health Organization prioritized focus and resources on reducing NCD mortality by strengthening health systems delivering NCD services. In a rapid assessment survey of service delivery for NCDs during the COVID-19 pandemic among 163 Ministries, 122 countries reported that NCD services are disrupted, thus now is the time for all countries to strive to build back better systems for the treatment of all patients with NCDs, including cancer (WHO, 2020).

The COVID-19 pandemic has resulted in formidable challenges to patients with cancer as well as clinicians and researchers. As the pandemic rages on across the world, it will be of paramount importance to further study the interactions of cancer and COVID-19 in order to better tailor the management of patients with cancer and minimize disruption to cancer care. The biological mechanisms that underlie the poor outcomes of patients with cancer remain poorly understood and require further research to help target therapeutic interventions in patients with cancer who develop COVID-19. Further research is also needed to determine whether the biological insights derived from the cancer research community can be translated into clinically effective treatments for all patients with COVID-19. Finally, most of the clinical data in this review originates from high-resource countries, reflecting the published literature, but more work is needed to guide the care of patients with cancer during the pandemic in low-resource settings. 

AACR COVID-19 response letter

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

Clinical Issues and Guidance [WWW Document

Joint Statement: Roadmap for Maintaining Essential Surgery during COVID-19 Pandemic [WWW Document

Quantifying the prevalence of SARS-CoV-2 long-term shedding among non-hospitalized COVID-19 patients

Screening for COVID-19 in Asymptomatic Patients with Cancer in a Hospital in the United Arab Emirates

ASCO Survey on COVID-19 in Oncology (ASCO) Registry [WWW Document

ASTRO, 2020. COVID-19 Recommendations and Information -American Society for Radiation Oncology (ASTRO) -American Society for Radiation Oncology (ASTRO)

Disparities in prostate cancer incidence and mortality rates: Solvable or not? Prostate

Disparities in Cancer Outcomes Due to COVID-19-A Tale of 2 Cities

No evidence that androgen regulation of pulmonary TMPRSS2 explains sex-discordant COVID-19 outcomes

Cytokines in clinical cancer immunotherapy

Decrease in ACE2 mRNA expression in aged mouse lung

Predicting infectious SARS-CoV-2 from diagnostic samples

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Certain Medical Conditions and Risk for Severe COVID-19 Illness | CDC [WWW Document

Flattening the curve in oncologic surgery: Impact of Covid-19 on surgery at tertiary care cancer center

Oncology Meets Immunology: The Cancer-Immunity Cycle

Effect of telehealth intervention on breast cancer patients' quality of life and psychological outcomes: A metaanalysis

Asians do not exhibit elevated expression or unique genetic polymorphisms for ACE2, the cell-entry receptor of SARS-CoVreleases/14867/2020-07-28/genentech-provides-an-update-on-the-phas

Perspectives on Oncology-Specific Language During the Coronavirus Disease

Effect of Cancer on Clinical Outcomes of Patients With COVID-19: A Meta-Analysis of Patient Data

Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Cancer Patient Care during COVID-19

COVID-19 in persons with haematological cancers

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2

Virtually perfect? Telemedicine for covid-19

Hydroxychloroquine for COVID-19-Preliminary Report Effect of Hydroxychloroquine in Hospitalized Patients

An interferon-γ-related cytokine storm in SARS patients

Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients-An Observational Study

Compassionate Use

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

Venous Thromboembolism and Cancer: Risks and Outcomes

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

Utility of COVID-19 Screening in Cancer Patients

Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients

COVID-19 impact on early career investigators: a call for action

Digitalized Adaptation of Oncology Trials during and after COVID-19

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Effects of the COVID-19 Pandemic on Cancer-Related Patient Encounters

Longitudinal analyses reveal immunological misfiring in severe COVID-19

cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis

Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers

COVID-19 in patients with lung cancer

Cytokine Storms: Understanding COVID-19

Dissecting racial disparities in multiple myeloma

Sex and Racial Disparities in the Treatment and Outcomes of Muscle-Invasive Bladder Cancer

The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study

Androgen receptor and androgen-dependent gene expression in lung

Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity

Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China

VTE in ICU Patients With COVID-19

Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study

Head and neck oncologic surgery in the <scp>COVID</scp> -19 pandemic: Our experience in

Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells

Rethinking Clinical Trials Reform During the COVID-19 Pandemic

Coronavirus Map: Tracking the Global Outbreak -The New York Times

SnapShot: COVID-19

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its J o u r n a l P r e -p r o o f immune cross-reactivity with SARS-CoV

Cancer datasets and the SARS-CoV-2 pandemic: Establishing principles for collaboration

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Does androgen deprivation therapy protect against severe complications from COVID-19?

Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID-19

Expression Is Increased in the Lungs of Patients With Comorbidities Associated With Severe COVID-19

Pulmonary Embolism in Patients with COVID-19: Awareness of an Increased Prevalence

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized COVID-19 Patients

Dysregulation of Immune Response in Patients With Coronavirus

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on lopinavir-ritonavir

Regeneron and Sanofi Provide Update on Kevzara® (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients | Regeneron Pharmaceuticals Inc

Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond. Curr

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Utilization of J o u r n a l P r e -p r o o f COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study

Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid

Infections in Cancer Patients with Solid Tumors: A Review

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

Telemedicine for Cancer Care in the Time of COVID-19

The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer

COVID-19 and haematological malignancy: navigating a narrow strait

Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: Neutropenia, humoral, and splenic defects

Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies

Oncology Practice during the COVID-19 Pandemic

Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential

Cytokine release syndrome

Cancer statistics, 2020. CA

NCI's Work to Advance Cancer Research while Responding to the COVID-19 Pandemic

Cigarette Smoke Exposure and Inflammatory Signaling Increase the Expression of the SARS-CoV-2 Receptor ACE2 in the Respiratory Tract

Implementation Guide for Rapid Integration of an Outpatient Telemedicine Program During the COVID-19 Pandemic

Tocilizumab for treatment of mechanically ventilated patients with COVID-19

TMPRSS2 and COVID-19: Serendipity or opportunity for intervention? Cancer Discov

Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic

Immune surveillance of tumors

Laboratory diagnosis of COVID-19: Current issues and challenges

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

Resuming bowel cancer screening post-COVID-19

Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study

The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute

Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials

Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer

Endothelial cell infection and endotheliitis in COVID-19

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an

How is biomedical research funding faring during the COVID-19 lockdown?

SARS-CoV-2 Viral Load Predicts Mortality in Patients with and Without Cancer Who Are Hospitalized with COVID-19

Thoracic Cancers International COVID-19 Collaboration

WHO, 2020. COVID-19 and NCDs

Factors associated with COVID-19-related death using OpenSAFELY

Multi-center evaluation of cepheid xpert® xpress SARS-CoV-2 point-of-care test during the SARS-CoV-2 pandemic

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Prediction models for diagnosis and prognosis of covid-19: Systematic review and critical appraisal

Infection Control of 2019 Novel Corona Virus Disease (COVID-19) in Cancer Patients undergoing Radiotherapy in Wuhan

COVID-19 and African Americans

Health and Racial Disparity in Breast Cancer

SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human